Portage Biotech Inc. PRTG
Set alert
At close · Sep 3
52-week range unavailable
- Open
- 7.60
- Prev close
- 6.81
- Mkt cap
- 6.04M
- Vol
- 371.67K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.81
- High
- 7.60
- Forward P/E
- -10.37
- Beta
- 99.48
- Short ratio
- 0.17
- Inst. own
- 17.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 27, 2024
- 50-d avg
- 5.09
- 200-d avg
- 5.60
- 1y target
- 0.00
Key statistics
- Market cap
- 6.04M
- Enterprise value
- 417.30K
- Trailing P/E
- 0.00
- Forward P/E
- -10.37
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.33
- EPS (TTM)
- -68.17
- Beta
- 99.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.34M
- Total cash
- 3.33M
- Total debt
- 37.00K
- Return on equity
- -191.03%
- Shares outstanding
- 1.12M
- Short % of float
- 1.42%
- 50-day average
- 5.09
- 200-day average
- 5.60
Analyst view
Consensus: none
Next earnings
Aug 27, 2024
Expected Aug 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | 0.00 | -1.26 | — | — |
| Aug 27, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 27, 2024 | Jun 1, 2024 | 0.00 | -1.58 | — | — |
| Aug 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Aug 15, 2024 | Mar 1, 2024 | 0.00 | -24.20 | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -5.40 | -3.60 | +1.80 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 8, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 29, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 31, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 2, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 1, 2023 | Cantor Fitzgerald | main | Overweight | Overweight |
About Portage Biotech Inc.
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- British Virgin Islands
- Website
- portagebiotech.com
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
- AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
- Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
- Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
- Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
- Portage Biotech and Compedica Stock-for-Stock Exchange
- Portage Biotech Stock Surges As It Prepares For Human Trial
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Your note
Sign in to keep a note on PRTG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Mintz (Steven Michael) | Director of Issuer | Acquisition or disposition in the public market | Mar 6, 2022 | 24,493 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bison Wealth, LLC | 9.39% | 98,521 | 531.03K | Sep 29, 2024 |
| Virtu Financial LLC | 1.04% | 10,919 | 58.85K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.96% | 10,058 | 54.21K | Sep 29, 2024 |
| Connective Capital Management LLC | 0.75% | 7,909 | 42.63K | Sep 29, 2024 |
| UBS Group AG | 0.24% | 2,466 | 13.29K | Sep 29, 2024 |
| Blackrock Inc. | 0.04% | 408 | 2.20K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 107 | 576 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 1 | 5 | Aug 30, 2024 |